Ekso Bionics (EKSO)
(Real Time Quote from BATS)
$1.24 USD
+0.03 (2.48%)
Updated Sep 24, 2024 03:52 PM ET
After-Market: $1.24 0.00 (0.00%) 4:10 PM ET
2-Buy of 5 2
D Value B Growth F Momentum D VGM
Income Statements
Fiscal Year end for Ekso Bionics Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 18 | 13 | 11 | 9 | 14 |
Cost Of Goods | 9 | 7 | 5 | 4 | 7 |
Gross Profit | 9 | 6 | 7 | 5 | 7 |
Selling & Adminstrative & Depr. & Amort Expenses | 24 | 22 | 21 | 18 | 23 |
Income After Depreciation & Amortization | -15 | -16 | -14 | -13 | -17 |
Non-Operating Income | 0 | 1 | 4 | -2 | 5 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -15 | -15 | -10 | -16 | -12 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -15 | -15 | -10 | -16 | -12 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -15 | -15 | -10 | -16 | -12 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -13 | -15 | -13 | -12 | -16 |
Depreciation & Amortization (Cash Flow) | 2 | 1 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -15 | -16 | -14 | -13 | -17 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 13.87 | 12.96 | 12.27 | 7.16 | 4.80 |
Diluted EPS Before Non-Recurring Items | -1.10 | -1.16 | -1.04 | -1.61 | -3.45 |
Diluted Net EPS (GAAP) | -1.10 | -1.16 | -0.88 | -2.21 | -2.55 |
Fiscal Year end for Ekso Bionics Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 4.95 | 3.76 | 4.85 | 4.61 | 4.70 |
Cost Of Goods | 2.31 | 1.81 | 2.48 | 2.15 | 2.45 |
Gross Profit | 2.64 | 1.95 | 2.37 | 2.46 | 2.25 |
SG&A, R&D, and Dept/Amort Expenses | 4.98 | 5.21 | 5.81 | 5.39 | 6.54 |
Income After SG&A, R&D, and Dept/Amort Expenses | -2.34 | -3.26 | -3.44 | -2.93 | -4.29 |
Non-Operating Income | -0.01 | -0.12 | 0.29 | -0.37 | 0.12 |
Interest Expense | 0.07 | 0.06 | 0.05 | 0.06 | 0.06 |
Pretax Income | -2.42 | -3.43 | -3.21 | -3.37 | -4.23 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -2.42 | -3.43 | -3.21 | -3.37 | -4.23 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -2.42 | -3.43 | -3.21 | -3.37 | -4.23 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 18.22 | 17.42 | 14.45 | 14.07 | 13.64 |
Diluted EPS Before Non-Recurring Items | -0.13 | -0.20 | -0.22 | -0.24 | -0.31 |
Diluted Net EPS (GAAP) | -0.13 | -0.20 | -0.22 | -0.24 | -0.31 |